Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bevacizumab Gamma→

Bevacizumab Gamma Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~149000 g/mol
Drug class
Humanised monoclonal antibodyvascular endothelial growth factor A (VEGF-A) inhibitor
Mechanism of action
Binds VEGF-A and prevents it from interacting with VEGF receptors on endothelial cells, inhibiting angiogenesis and reducing tumour-associated vascular permeability. Product-specific biosimilar status does not change the bevacizumab active moiety.
Indications / reported uses
  • Oncology indications for bevacizumab products are tumour- and combination-specific, including selected colorectal, lung, renal, ovarian and cervical cancers; assign only the indications listed in the current product-specific biosimilar label and jurisdiction
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Bevacizumab Gamma Environmental Risk Assessment (ERA) (the Bevacizumab Gamma ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.